Search

Zhijian “James” Chen, Ph.D., Professor of Molecular Biology at UT Southwestern Medical Center and one of the world’s top researchers on how the body’s immune system protects us against threats such as bacteria and viruses, has been awarded the 2026 Japan Prize in Life Sciences – one of the highest

UT Southwestern has received the 2020 Health Professions Higher Education Excellence in Diversity (HEED) Award from INSIGHT Into Diversity magazine, the oldest and largest diversity-focused publication in higher education.

UT Southwestern Medical Center is one of the 10 best large employers in the United States and among the top 5 health care employers, according to the America’s Best Employers 2022 list compiled by Forbes and Statista.

A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.

Dr. Stephanie Tow, M.D., completed her first week of providing volunteer care at the Tokyo 2020 Olympics.

Zhijian “James” Chen, Ph.D., Professor of Molecular Biology at UT Southwestern Medical Center, has been awarded the 2023 Louisa Gross Horwitz Prize in recognition of his groundbreaking work on innate immunity.

Ravikanth Maddipati, M.D., Assistant Professor of Internal Medicine and in Children’s Medical Center Research Institute at UT Southwestern, has been awarded $1.5 million from the National Institutes of Health (NIH) to support research investigating positional heterogeneity in cancer, or how tumors

More than 225,000 tweets with the hashtags #scamdemic and #plandemic led to an “infodemic” of misinformation and disinformation on Twitter during the first year of the pandemic, according to a study by UT Southwestern researchers published in PLOS ONE.

Physician researchers from UT Southwestern Medical Center have developed an innovative nanotherapeutic drug that prevents cancer from spreading to the liver.

UT Southwestern Simmons Cancer Center researchers have developed technology that is spawning a much better form of drug delivery for gene therapy and has achieved a 43 percent increase in the survival of mice with glioblastoma, one of the deadliest forms of human brain cancer.